These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 28643430)

  • 1. Platinum-containing regimens for metastatic breast cancer.
    Egger SJ; Willson ML; Morgan J; Walker HS; Carrick S; Ghersi D; Wilcken N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD003374. PubMed ID: 28643430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum-containing regimens for triple-negative metastatic breast cancer.
    Egger SJ; Chan MMK; Luo Q; Wilcken N
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013750. PubMed ID: 33084020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum containing regimens for metastatic breast cancer.
    Carrick S; Ghersi D; Wilcken N; Simes J
    Cochrane Database Syst Rev; 2004; (3):CD003374. PubMed ID: 15266482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum containing regimens for metastatic breast cancer.
    Carrick S; Ghersi D; Wilcken N; Simes J
    Cochrane Database Syst Rev; 2004; (2):CD003374. PubMed ID: 15106201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
    Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
    Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxanes for adjuvant treatment of early breast cancer.
    Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
    Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab-containing regimens for metastatic breast cancer.
    Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
    Vasconcellos VF; Marta GN; da Silva EM; Gois AF; de Castria TB; Riera R
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD009256. PubMed ID: 31930743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B; Wong MH; Willson ML; Stockler MR; Pavlakis N; Goodwin A
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD003474. PubMed ID: 29082518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single agent versus combination chemotherapy for metastatic breast cancer.
    Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Newhouse R; Nelissen E; El-Shakankery KH; Rogozińska E; Bain E; Veiga S; Morrison J
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD006910. PubMed ID: 37407274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy for advanced gastric cancer.
    Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.